Expect $125-150 mn from oral contraceptives business: Lupin
Lupin has received approval to launch the generic version of oral contraceptive Yasmin in the US. Ramesh Swaminathan, president of finance and planning, Lupin, explains this is a crucial product for the pharma company and could help them garner $125-150 million dollars over time. He adds that Lupin has a strong pipeline of launches for the year ahead as well.
![Gadgets 360 With Technical Guruji: Did You Know? [October 5, 2024]](https://c.ndtvimg.com/2024-10/khm6ijp8_did-you-know_160x120_05_October_24.jpg?downsize=355∶533 "Gadgets 360 With Technical Guruji: Did You Know? [October 5, 2024]")
![Gadgets 360 With Technical Guruji: News of the Week [October 5, 2024]](https://c.ndtvimg.com/2024-10/jgj2u8h_news-of-the-week_160x120_05_October_24.jpg?downsize=355∶533 "Gadgets 360 With Technical Guruji: News of the Week [October 5, 2024]")
